

Calcium Homeostasis and Vitamin D:  
*What Are Vitamin D Tests  
Actually Measuring?*

---

**Joely Straseski, PhD, MS, MT(ASCP), DABCC**  
**University of Utah and ARUP Laboratories**  
**Salt Lake City, Utah**



# Outline:


- Background, deficiency
- How much is enough?
- What should we be measuring?
- How do methods compare to each other?
- Measurement issues
- Standardization efforts



# VITAMIN D: BACKGROUND




# Calcium Homeostasis:




- Dynamic process...not static
- 99% stored in bone
- Remaining 1%:
  - Slowly exchanged
  - Rapidly exchanged
    - 50% = ionized (bioactive)
    - 40% = protein-bound (albumin, globulins)
    - 10% = anion-bound (bicarb, phos, citrate, lactate)
- Ionized and anion-bound forms pass through glomerulus

# Calcium Sensing: Parathyroid Glands


- Predominant hormone in calcium homeostasis:  
Parathyroid Hormone (PTH)
- Calcium sensing receptors (CaSR)



ADAM.




# Endocrine Control of $\text{Ca}^{2+}$ Homeostasis:



[http://biology.clc.uc.edu/fankhauser/Labs/Anatomy\\_&\\_Physiology/A&P202/202\\_lecture\\_notes/calcium\\_regulation.jpg](http://biology.clc.uc.edu/fankhauser/Labs/Anatomy_&_Physiology/A&P202/202_lecture_notes/calcium_regulation.jpg)

# Vitamin D's Role in Calcium Homeostasis:



# Causes of Vitamin D Deficiency:


- Deficient intake or absorption
  - Dietary (few sources), malnutrition
  - Inadequate sunlight exposure
  - Malabsorption
  - Gastrectomy
  - Small bowel disease
  - Pancreatic insufficiency
- Defective 25-hydroxylation
  - Alcoholic, biliary cirrhosis
  - Anticonvulsants
- Loss of vitamin D binding protein(VDBP)
  - Nephrotic syndrome
- Practical matters
  - Increased use of sunscreen
  - Increased indoor activities
  - Geography
  - Seasonality






# Who is at risk for Vitamin D deficiency?

- Females
- Elderly
- People of color
- 37<sup>th</sup> parallel
- Hospitalized, indoors
- Covered
- Infants, especially breast fed
- Obese



# Effect of Age on Vitamin D:

- Vitamin D levels in response to whole-body exposure to simulated sunlight:




# Effect of Ethnicity on Vitamin D:

NCHS Data Brief ■ No. 59 ■ March 2011

## Vitamin D Status: United States, 2001–2006

Anne C. Looker, Ph.D.; Clifford L. Johnson, M.P.H.; David A. Lacher, M.D.; Christine M. Pfeiffer, Ph.D.;  
Rosemary L. Schleicher, Ph.D.; and Christopher T. Sempos, Ph.D.


Figure 4. Age- and season-adjusted prevalence at risk of deficiency and inadequacy among persons aged 1 year and over: United States, 2001–2006



<sup>2</sup> $p < 0.05$  compared with non-Hispanic white persons.

SOURCE: CDC/NCHS, National Health and Nutrition Examination Survey (NHANES); data for ages 1–5 years from NHANES 2003–2006.

# Effect of UV on Vitamin D:



**TABLE 2.** Indications for 25(OH)D measurement (candidates for screening)

Rickets  
Osteomalacia  
Osteoporosis  
Chronic kidney disease  
Hepatic failure  
Malabsorption syndromes  
    Cystic fibrosis  
    Inflammatory bowel disease  
    Crohn's disease  
    Bariatric surgery  
    Radiation enteritis  
Hyperparathyroidism  
Medications  
    Antiseizure medications  
    Glucocorticoids  
    AIDS medications  
    Antifungals, e.g. ketoconazole  
    Cholestyramine  
African-American and Hispanic children and adults  
Pregnant and lactating women  
Older adults with history of falls  
Older adults with history of nontraumatic fractures  
Obese children and adults (BMI > 30 kg/m<sup>2</sup>)  
Granuloma-forming disorders  
    Sarcoidosis  
    Tuberculosis  
    Histoplasmosis  
    Coccidiomycosis  
    Berylliosis  
Some lymphomas




# Deficiency Statistics: United States

NCHS Data Brief ■ No. 59 ■ March 2011

## Vitamin D Status: United States, 2001–2006

Anne C. Looker, Ph.D.; Clifford L. Johnson, M.P.H.; David A. Lacher, M.D.; Christine M. Pfeiffer, Ph.D.;  
Rosemary L. Schleicher, Ph.D.; and Christopher T. Sempos, Ph.D.



# Benefits Associated With Vitamin D:

- Lower cardiovascular mortality
- Reduced risk of:
  - Autoimmune diseases
    - DM, MS, allergy, asthma
  - Cardiovascular disorders
  - Infectious diseases
  - Cancers
  - Renal disease (in African Americans)
  - Mental illness
- Granuloma-forming disorders
- Lower mortality rate
- *...and many more*

## Important:

Only skeletal effects have been positively associated with vitamin D concentrations.

## The Nonskeletal Effects of Vitamin D: An Endocrine Society Scientific Statement

Clifford J. Rosen, John S. Adams, Daniel D. Bikle, Dennis M. Black, Marie B. Demay, JoAnn E. Manson, M. Hassan Murad, and Christopher S. Kovacs

In summary, not surprisingly there remains a persistent need for large randomized controlled trials and dose-response data to test the effects of vitamin D on chronic disease outcomes including autoimmunity, obesity, diabetes mellitus, hypertension, and heart disease. The VITAL trial, as noted above, could help determine whether higher doses of vitamin D (*i.e.*, 2000 IU/d) will reduce the risk of osteoporosis, cancer, and CVD. Similarly, a very large, placebo-controlled, randomized trial of vitamin D, 4000 IU/d, to prevent the onset of type 2 diabetes mellitus in prediabetics is currently in the planning stage. Any potential benefit of high-dose vitamin D supplementation on maternal or fetal outcomes will also await larger trials. Notwithstanding, large-scale clinical trials of a single nutrient may not fully answer the many questions inherent in vitamin D actions. Thus, the role of vitamin D supplementation in the prevention and treatment of chronic nonskeletal diseases remains to be determined.





# Vitamin D Benefits: Recent Statements



- “Vitamin D Deficiency: Screening”
  - Draft recommendation statement
  - Public comment period ended 7/21/2014

“The USPSTF concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for vitamin D deficiency.”

# Vitamin D Benefits: Recent Statements

**September, 2014**

*Evidence Report/Technology Assessment*

Number 217



## **Vitamin D and Calcium: A Systematic Review of Health Outcomes (Update)**

- 154 primary articles
- 2 systematic reviews



Agency for Healthcare Research and Quality  
Advancing Excellence in Health Care • [www.ahrq.gov](http://www.ahrq.gov)

Evidence-Based  
Practice

...“inconsistent evidence regarding the effect of vitamin D alone or in combination with calcium on most health outcomes”

Findings are “inconsistent across studies for bone health; breast, colorectal, and prostate cancer; cardiovascular disease and mortality; immune function; and pregnancy-related outcomes.”

Vitamin D and calcium supplementation may have “positive effects on bone mineral density and bone mineral content.”

# Risks of Excessive Vitamin D:

- Sunshine can provide up to 10,000 IU/day
- 100 IU/day raises serum concentration of 25(OH)D by 1 ng/mL
- Serum 25(OH)D is safe up to 100 ng/mL and perhaps 200 or 300 ng/mL
  - Toxic levels are reported at 150 ng/mL
- 10,000 IU/day Tolerable Upper Intake Level (no toxicity observed up to 5 months)
- Increased risk of kidney stones with excess calcium intake (1000 mg)
- IOM states > 4000 IU/day increases risk for harm
- Little evidence from existing trials that excess vitamin D intake is harmful


*Vitamin D  
toxicosis is  
extremely  
rare.*



# VITAMIN D: HOW MUCH IS ENOUGH?



# Why is this so difficult?



- Can't we just measure 120 healthy adults, create a histogram and determine the mean  $\pm$  2SD...like any other reference range?
- Not that easy...
  - What parallel do you live on?
  - Is it summer or winter?
  - Are your subjects lifeguards or office workers?
  - “normal” vs. “optimal”
- *Note: We use decision limits, not reference intervals, to describe Vitamin D concentrations.*




SPECIAL FEATURE

Clinical Practice Guideline

## Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline

Michael F. Holick, Neil C. Binkley, Heike A. Bischoff-Ferrari, Catherine M. Gordon, David A. Hanley, Robert P. Heaney, M. Hassan Murad, and Connie M. Weaver

Boston University School of Medicine (M.F.H.), Boston, Massachusetts 02118; University of Wisconsin (N.C.B.), Madison, Wisconsin 53706; University Hospital Zurich (H.A.B.-F.), CH-8091 Zurich, Switzerland; Children's Hospital Boston (C.M.G.), Boston, Massachusetts 02115; University of Calgary Faculty of Medicine (D.A.H.), Calgary, Alberta, Canada T2N 1N4; Creighton University (R.P.H.), Omaha, Nebraska 68178; Mayo Clinic (M.H.M.), Rochester, Minnesota 55905; and Purdue University (C.M.W.), West Lafayette, Indiana 47907



IOM (Institute of Medicine), 2011. Washington, DC: The National Academies Press; J Clin Endocrinol Metab 2011;96:1911-30

# Vitamin D: Recommended Ranges

Clinical Condition	Institute of Medicine (IOM) (General population)	Endocrine Society (Population at risk for deficiency)
Deficiency	<12 ng/mL (<30 nmol/L)	<20 ng/mL (50 nmol/L)
Insufficiency	12-20 ng/mL (30 - 50 nmol/L)	21-29 ng/mL (52.5 - 72.5 nmol/L)
Sufficiency	≥20 ng/mL (≥50 nmol/L)	>30 ng/mL (75 nmol/L)
Upper limit	50 ng/mL (125 nmol/L)	100 ng/mL (250 nmol/L)

**No consensus.**

# VITAMIN D: WHAT TO MEASURE?





# What form should be measured?

- **Circulating serum 25(OH) vitamin D** – best available indicator of cutaneous synthesis (sunlight, skin) and total intake (food, supplements)
  - Remember:  $25(\text{OH})\text{D} = 25(\text{OH})\text{D}_2 + 25(\text{OH})\text{D}_3$ 
    - Major circulating form, long half-life
    - Measures storage, not function
- Because of the widespread use of both vitamin D<sub>2</sub> and vitamin D<sub>3</sub> supplements, **assays should measure 25(OH) vitamin D<sub>2</sub> and 25(OH) vitamin D<sub>3</sub> equally**

# What should NOT be measured?

- Parent vitamin D
  - Precursor
  - Protein bound
  - Water insoluble
  - Lower circulating concentrations
- 1,25(OH)<sub>2</sub> vitamin D
  - Bioactive form
  - Short half-life

## Remember:

25(OH) vitamin D concentrations correlate best with clinical signs of vitamin D deficiency

# Clarifying Nomenclature:

When someone says...	This is being measured...
“Vitamin D <sub>2</sub> ”	25(OH)D <sub>2</sub>
“Vitamin D <sub>3</sub> ”	25(OH)D <sub>3</sub>
“Total Vitamin D”	25(OH)D <sub>2</sub> + 25(OH)D <sub>3</sub>



*Not the “parent” vitamin D prohormone...*



# **VITAMIN D: HOW DO DIFFERENT METHODS COMPARE WITH EACH OTHER?**



# Biases Between Methods: A Historical Problem



- 59 postmenopausal women (similar age, race, geographic residence, bone mass)
- 62 measurements, 2 laboratories, 2 assays
- No overlap between groups (90% vs. 17% insufficiency)

Total 25(OH)D

	Supplier	Strengths	Limitations <sup>a</sup>
<b>Automated immunoassay</b>			
Liaison Total	Diasorin	Extensively used Technically simple High throughput	Susceptible to matrix effects Possible between lot variability in product
iSYS	IDS	Technically simple High throughput	Susceptible to matrix effects Under-recovers 25-hydroxyvitamin D2 Possible between lot variability in product
Elecys	Roche	Technically simple High throughput	Susceptible to matrix effects Only detects 25-hydroxyvitamin D3 Possible between lot variability in product









25(OH)D<sub>2</sub>, 25(OH)D<sub>3</sub>

<b>Direct detection methods</b>			
HPLC	Usually developed or adapted 'in-house'	Solvent or solid phase extraction followed by and interferences Process can be automated or semi-automated Separate simultaneous measurement of 25OHD2 and 25OHD3 User able to control standardisation Low reagent costs	Requires specialised staff  Some procedures require large sample volume.  Lower sample throughput and relatively longer turnaround time compared to immunoassay Possible interference from C3-25OHD epimer
LC/MS/MS	Usually developed or adapted 'in-house'	Solvent or solid phase extraction followed by chromatography minimises matrix effects and interferences Process can be automated or semi-automated User able to control standardisation  Separate simultaneous measurement of 25OHD2 and 25OHD3 Highly accurate and precise when properly validated	Equipment is expensive  Requires specialised staff  Lower sample throughput and relatively longer turnaround time compared to immunoassay Susceptible to ion suppression interference  Possible interference from C3-25OHD epimer

Adapted from: Wallace AM, et al. Steroids 2010;75:477-88

# Method Comparisons: Automated Immunoassays

- Many new commercial assays
- Differences between methods
- Both positive and negative biases



# VITAMIN D: MEASUREMENT ISSUES





# Why are there differences between vitamin D methods?




- Non-equimolar detection of 25(OH) vitamin D<sub>2</sub> and D<sub>3</sub>
- Vitamin D binding protein and proprietary methods of release (hydrophobic)
- Cross-reactivity with metabolites, including 3-epi-25(OH) vitamin D<sub>3</sub>
- Heterophilic antibody interferences
- Differences in standardization – historical lack of international standard




# Non-equimolar Detection of D<sub>2</sub> and D<sub>3</sub>: Comparison to an HPLC Method

Over-estimates




Under-estimates



# Vitamin D Binding Protein (DBP):


- Tightly binds 25(OH) vitamin D
- Release prior to testing
- Relationship between DBP and deviation from MS
- Elevated DBP:
  - Pregnancy
- Decreased DBP:
  - ICU patients
- Ethnic differences<sup>1</sup>




<sup>1</sup>Powe CE et al. NEJM 2013;369:1991

Heijboer AC et al. Clin Chem 2012;58:543-8

# Vitamin D Metabolite: C3-epimer



# C3 Epimer as a Function of Age:




Singh RJ, et al. JCEM 2006;91:3055-61

- 3-epi-25(OH)D<sub>3</sub> concentrations
  - 15 – 41% of infant samples
  - 2.5 – 17% of adult samples
    - CCLM 2011;49:253-6
  - Present in 99% of samples from patients neonate to >80 yrs
  - ≤ 3 ng/mL in 92% of samples
    - JCEM 2012;97:163-8

# Vitamin D: Proficiency Testing Programs

- Goal: Ensure reliability of 25(OH) vitamin D measurements...regardless of the assay used



- College of American Pathologists (CAP)
  - Accuracy Based Vitamin D (ABVD) survey
- Vitamin D External Quality Assessment Scheme (DEQAS)
- NIST-NIH Vitamin D Metabolites Quality Assurance Program (VitDQAP)
- Quality Management Program-Laboratory Services (QMP-LS)

# Proficiency Testing Programs: College of American Pathologists (CAP)

- Accuracy-Based Vitamin D (ABVD) survey
  - Pooled, fresh frozen serum samples
    - Supplemented with oral vitamin D<sub>2</sub>
  - Target values: CDC LC-MS/MS method
    - Traceable to NIST and University of Ghent reference methods
  - Acceptance criteria =  $\pm 25\%$  of target value



# CAP Accuracy Based Vitamin D (ABVD) Survey A: April, 2014

Sample	25 (OH) Vitamin D (ng/mL) - Target			
	Total	D <sub>2</sub>	D <sub>3</sub>	D <sub>3</sub> -Epimer
ABVD-07	59.18	0.49	58.69	5.6
ABVD-08	14.52	4.42	10.10	0.9
ABVD-09	18.99	1.11	17.88	2.1


- Improved agreement over non-commutable materials
- Variation among manufacturers
- Under-recovery of 25(OH) vitamin D<sub>2</sub>
- Over-recovery in presence of C3-epimer





# Vitamin D External Quality Assessment Scheme: DEQAS

DEQAS January 2014 - 25OHD Method Means (+/-1SD) for Major Method Groups



# VITAMIN D: STANDARDIZATION AMONG METHODS



# Toward Vitamin D Standardization:

- “A standardized laboratory measurement is one that is accurate and comparable over time, location and laboratory procedure.” --NIH, VDSP
- Milestones:
  - Reference method procedure
    - NIST, University of Ghent
  - NIST Standard Reference Material (SRM 972 and 2972)
  - CDC Vitamin D Standardization Program (VDSP)
    - Vitamin D Certification Program
  - CDC Hormone Standardization Program (HoSt)



# Summary:

- 25(OH) vitamin D concentrations correlate best with clinical signs of vitamin D deficiency
- Extra-skeletal benefits of vitamin D are not well substantiated
- There is no consensus on optimal recommended serum 25(OH) vitamin D concentrations
- Vitamin D methods should ideally measure D<sub>2</sub> and D<sub>3</sub> metabolites equally
- Separating D<sub>2</sub> and D<sub>3</sub> concentrations may aid in monitoring therapy
- Standardization of methods is necessary
  - Differences still exist among methods



# Questions?

Joely Straseski, PhD, MS, MT(ASCP), DABCC

Assistant Professor of Pathology

Medical Director, Endocrinology

Co-Medical Director, Automated Core Laboratory

ARUP Laboratories and University of Utah

